Login to Your Account

Tysabri Withdrawal Clouds Future For Recovering Elan

By Cormac Sheridan

Wednesday, March 9, 2005
DUBLIN, Ireland - Confirmation of a second case of progressive multifocal leukoencephalopathy (PML) among the 1,171 multiple sclerosis patients receiving Tysabri (natalizumab) in combination with Avonex (interferon beta-1a) sent shares of Elan Corp. plc and Biogen Idec Inc. further downward last Friday. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription